Originally developed to treat type 2 diabetes, GLP-1 receptor agonists have rapidly become a cornerstone of obesity management, fundamentally altering the trajectory of U.S. healthcare. Their surging popularity is driving shifts in clinical practice, insurance coverage dynamics, and public health policy nationwide.
Also Read
- Volker Turk Wins Second Term as UN Human Rights Chief Amid Israeli Opposition
- Israeli Forces Detain Dozens in West Bank Crackdown Following Deadly Attack
- Trip.com Penalized by SAMR Over Violations in Online Hotel Booking Practices
- Voices of Defiance: Understanding the Diverse Faces Behind India’s Student Protests
